1,932 research outputs found

    Well-defined molecular uranium(III) chloride complexes

    Get PDF
    The first anhydrous molecular complexes of uranium(III) chloride, soluble in polar aprotic solvents, are reported, including the structures of the dimeric [UCl3(py)4]2 and the trimetallic [UCl(py)4(μ-Cl)3U(py)2(μ-Cl)3UCl2(py)3]

    Reductive disproportionation of nitric oxide mediated by low-valent uranium

    Get PDF
    The reductive disproportionation of nitric oxide (1 atm) is mediated by the bulky UIII aryloxide [UIII(OArAd,Ad,Me)3] (Ad,Ad,MeArO = O-C6H2-2,6-Ad-4-Me) (1) to form the UV terminal oxo species [(Ad,Ad,MeArO)3UV(O)] (2) and N2O, as confirmed by single crystal X-ray diffraction and GC-MS measurements. The reaction is quantitative in the solid state. Mechanistic and theoretical studies of the reaction suggest that the N–N bond is formed by the coupling of an η1-O bound nitric oxide ligand with gaseous NO to give an η1-(N2O2)1− intermediate prior to the spontaneous extrusion of N2O to yield the UV terminal oxo species 2

    Charge control of the inverse trans-influence

    Get PDF
    The synthesis and characterization of uranium(VI) mono(imido) complexes, by the oxidation of corresponding uranium(V) species, are presented. These experimental results, paired with DFT analyses, allow for the comparison of the electronic structure of uranium(VI) mono(oxo) and mono(imido) ligands within a conserved ligand framework and demonstrate that the magnitude of the ground state stabilization derived from the inverse trans-influence (ITI) is governed by the relative charge localization on the multiply bonded atom or group

    High precision X-ray logN-logS distributions: implications for the obscured AGN population

    Get PDF
    We have constrained the extragalactic source count distributions over a broad range of X-ray fluxes and in various energy bands to test whether the predictions from X-ray background synthesis models agree with the observational constraints provided by our measurements. We have used 1129 XMM-Newton observations at |b|>20 deg covering a sky area of 132.3 deg^2 to compile the largest complete samples of X-ray objects to date in the 0.5-1 keV, 1-2 keV, 2-4.5 keV, 4.5-10 keV, 0.5-2 keV and 2-10 keV energy bands. Our survey includes in excess of 30,000 sources down to ~10^-15 erg/cm^2/s below 2 keV and down to ~10^{-14} erg/cm^2/s above 2 keV. A break in the source count distributions was detected in all energy bands except the 4.5-10 keV band. An analytical model comprising 2 power-law components cannot adequately describe the curvature seen in the source count distributions. The shape of the logN(>S)-logS is strongly dependent on the energy band with a general steepening apparent as we move to higher energies. This is due to non-AGN populations, comprised mainly of stars and clusters of galaxies, contribute up to 30% of the source population at energies 10^{-13} erg/cm^2/s, and these populations of objects have significantly flatter source count distributions than AGN. We find a substantial increase in the relative fraction of hard X-ray sources at higher energies, from >55% below 2 keV to >77% above 2 keV. However the majority of sources detected above 4.5 keV still have significant flux below 2 keV. Comparison with predictions from the synthesis models suggest that the models might be overpredicting the number of faint absorbed AGN, which would call for fine adjustment of some model parameters such as the obscured to unobscured AGN ratio and/or the distribution of column densities at intermediate obscuration.Comment: Accepted for publication in Astronomy and Astrophysics. Abridged Abstract. 23 pages, 47 figures, 8 table

    Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study

    Get PDF
    Background: Adrenomedullin (ADM) regulates vascular tone and endothelial permeability during sepsis. Levels of circulating biologically active ADM (bio-ADM) show an inverse relationship with blood pressure and a direct relationship with vasopressor requirement. In the present prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock 1 (, AdrenOSS-1) study, we assessed relationships between circulating bio-ADM during the initial intensive care unit (ICU) stay and short-term outcome in order to eventually design a biomarker-guided randomized controlled trial. Methods: AdrenOSS-1 was a prospective observational multinational study. The primary outcome was 28-day mortality. Secondary outcomes included organ failure as defined by Sequential Organ Failure Assessment (SOFA) score, organ support with focus on vasopressor/inotropic use, and need for renal replacement therapy. AdrenOSS-1 included 583 patients admitted to the ICU with sepsis or septic shock. Results: Circulating bio-ADM levels were measured upon admission and at day 2. Median bio-ADM concentration upon admission was 80.5 pg/ml [IQR 41.5-148.1 pg/ml]. Initial SOFA score was 7 [IQR 5-10], and 28-day mortality was 22%. We found marked associations between bio-ADM upon admission and 28-day mortality (unadjusted standardized HR 2.3 [CI 1.9-2.9]; adjusted HR 1.6 [CI 1.1-2.5]) and between bio-ADM levels and SOFA score (p < 0.0001). Need of vasopressor/inotrope, renal replacement therapy, and positive fluid balance were more prevalent in patients with a bio-ADM > 70 pg/ml upon admission than in those with bio-ADM ≤ 70 pg/ml. In patients with bio-ADM > 70 pg/ml upon admission, decrease in bio-ADM below 70 pg/ml at day 2 was associated with recovery of organ function at day 7 and better 28-day outcome (9.5% mortality). By contrast, persistently elevated bio-ADM at day 2 was associated with prolonged organ dysfunction and high 28-day mortality (38.1% mortality, HR 4.9, 95% CI 2.5-9.8). Conclusions: AdrenOSS-1 shows that early levels and rapid changes in bio-ADM estimate short-term outcome in sepsis and septic shock. These data are the backbone of the design of the biomarker-guided AdrenOSS-2 trial. Trial registration: ClinicalTrials.gov, NCT02393781. Registered on March 19, 2015

    The exchangeability of shape

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Landmark based geometric morphometrics (GM) allows the quantitative comparison of organismal shapes. When applied to systematics, it is able to score shape changes which often are undetectable by traditional morphological studies and even by classical morphometric approaches. It has thus become a fast and low cost candidate to identify cryptic species. Due to inherent mathematical properties, shape variables derived from one set of coordinates cannot be compared with shape variables derived from another set. Raw coordinates which produce these shape variables could be used for data exchange, however they contain measurement error. The latter may represent a significant obstacle when the objective is to distinguish very similar species.</p> <p>Results</p> <p>We show here that a single user derived dataset produces much less classification error than a multiple one. The question then becomes how to circumvent the lack of exchangeability of shape variables while preserving a single user dataset. A solution to this question could lead to the creation of a relatively fast and inexpensive systematic tool adapted for the recognition of cryptic species.</p> <p>Conclusions</p> <p>To preserve both exchangeability of shape and a single user derived dataset, our suggestion is to create a free access bank of reference images from which one can produce raw coordinates and use them for comparison with external specimens. Thus, we propose an alternative geometric descriptive system that separates 2-D data gathering and analyzes.</p

    Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life

    Get PDF
    ImportanceThe utility of antihypertensives and ideal blood pressure (BP) for dementia prevention in late life remains unclear and highly contested.ObjectivesTo assess the associations of hypertension history, antihypertensive use, and baseline measured BP in late life (age &amp;amp;gt;60 years) with dementia and the moderating factors of age, sex, and racial group.Data Source and Study SelectionLongitudinal, population-based studies of aging participating in the Cohort Studies of Memory in an International Consortium (COSMIC) group were included. Participants were individuals without dementia at baseline aged 60 to 110 years and were based in 15 different countries (US, Brazil, Australia, China, Korea, Singapore, Central African Republic, Republic of Congo, Nigeria, Germany, Spain, Italy, France, Sweden, and Greece).Data Extraction and SynthesisParticipants were grouped in 3 categories based on previous diagnosis of hypertension and baseline antihypertensive use: healthy controls, treated hypertension, and untreated hypertension. Baseline systolic BP (SBP) and diastolic BP (DBP) were treated as continuous variables. Reporting followed the Preferred Reporting Items for Systematic Review and Meta-Analyses of Individual Participant Data reporting guidelines.Main Outcomes and MeasuresThe key outcome was all-cause dementia. Mixed-effects Cox proportional hazards models were used to assess the associations between the exposures and the key outcome variable. The association between dementia and baseline BP was modeled using nonlinear natural splines. The main analysis was a partially adjusted Cox proportional hazards model controlling for age, age squared, sex, education, racial group, and a random effect for study. Sensitivity analyses included a fully adjusted analysis, a restricted analysis of those individuals with more than 5 years of follow-up data, and models examining the moderating factors of age, sex, and racial group.ResultsThe analysis included 17 studies with 34 519 community dwelling older adults (20 160 [58.4%] female) with a mean (SD) age of 72.5 (7.5) years and a mean (SD) follow-up of 4.3 (4.3) years. In the main, partially adjusted analysis including 14 studies, individuals with untreated hypertension had a 42% increased risk of dementia compared with healthy controls (hazard ratio [HR], 1.42; 95% CI 1.15-1.76; P = .001) and 26% increased risk compared with individuals with treated hypertension (HR, 1.26; 95% CI, 1.03-1.53; P = .02). Individuals with treated hypertension had no significant increased dementia risk compared with healthy controls (HR, 1.13; 95% CI, 0.99-1.28; P = .07). The association of antihypertensive use or hypertension status with dementia did not vary with baseline BP. There was no significant association of baseline SBP or DBP with dementia risk in any of the analyses. There were no significant interactions with age, sex, or racial group for any of the analyses.Conclusions and RelevanceThis individual patient data meta-analysis of longitudinal cohort studies found that antihypertensive use was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls
    corecore